RxDoctor Payments Data

Peter Hui, MD

Cardiovascular Disease · San Francisco, CANPI 1619988375

Payments from drug & device makers

$21,536in general payments, 2019–2025

Across 75 payments — averaging $287.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi US Services Inc.$19K
  • Medtronic$774
  • Abiomed$244
  • Shockwave Medical, Inc$228
  • Abbott$221
  • Boston Scientific$209
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$2,801100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,536 in reported general payments places this provider in the 80th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$394,025
Medicare patients
1,299
Services billed
3,709

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban452$573,852
EntrestoSacubitril/Valsartan132$152,818
OpsumitMacitentan12$148,947
XareltoRivaroxaban66$94,939
Repatha SureclickEvolocumab82$55,977
JardianceEmpagliflozin45$43,063
Praluent PenAlirocumab46$32,263
FarxigaDapagliflozin Propanediol25$18,456
Rosuvastatin Calcium499$11,667
Ezetimibe457$11,645
Repatha PushtronexEvolocumab11$11,369
Atorvastatin Calcium821$8,582
Metoprolol Succinate396$8,291
Losartan Potassium285$4,600
Amlodipine Besylate432$3,767

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$22$573,852452 claims
Johnson & JohnsonXarelto$175$94,93966 claims
Boehringer IngelheimJardiance$58$43,06345 claims
AstraZenecaFarxiga$22$18,45625 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →